Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
2020
Historique:
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 31 7 2020
Statut: ppublish

Résumé

Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option.

Identifiants

pubmed: 32378656
doi: 10.2169/internalmedicine.4096-19
pmc: PMC7270753
doi:

Substances chimiques

Antiprotozoal Agents 0
liposomal amphotericin B 0
Amphotericin B 7XU7A7DROE

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1227-1230

Références

Acta Trop. 2011 May;118(2):87-96
pubmed: 21420925
J R Army Med Corps. 2005 Jun;151(2):73-80
pubmed: 16097110
Parasitol Int. 2018 Feb;67(1):34-37
pubmed: 28288843
Clin Infect Dis. 2011 Oct;53(7):693-5
pubmed: 21890773
Clin Infect Dis. 2013 Aug;57(3):370-80
pubmed: 23633111
PLoS Negl Trop Dis. 2017 Dec 14;11(12):e0006052
pubmed: 29240765
Parasitology. 2004 May;128(Pt 5):483-91
pubmed: 15180316
Clin Infect Dis. 2016 Dec 15;63(12):e202-e264
pubmed: 27941151
Curr Treat Options Infect Dis. 2015 Mar 1;7(1):52-62
pubmed: 25788870
J Am Acad Dermatol. 2013 Feb;68(2):284-9
pubmed: 22858005
Int J Dermatol. 2011 Nov;50(11):1336-42
pubmed: 22004484
Clin Infect Dis. 2017 Jan 1;64(1):67-71
pubmed: 27803094
Antimicrob Agents Chemother. 2012 Feb;56(2):1031-41
pubmed: 22123699
Dermatol Clin. 2015 Jul;33(3):579-93
pubmed: 26143433
Am J Trop Med Hyg. 2010 Nov;83(5):1028-33
pubmed: 21036832
PLoS Negl Trop Dis. 2010 Dec 21;4(12):e912
pubmed: 21200420
Int J Infect Dis. 2010 Dec;14(12):e1032-9
pubmed: 20952234

Auteurs

Atsushi Kosaka (A)

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

Naoya Sakamoto (N)

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

Mayu Hikone (M)

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

Kazuo Imai (K)

Department of Infectious Diseases and Infection Control, Saitama Medical University, Japan.
Center for Clinical Infectious Diseases and Research, Saitama Medical University, Japan.

Masayuki Ota (M)

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

Takuya Washino (T)

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

Takuya Maeda (T)

Department of Microbiology, Saitama Medical University, Japan.

Sentarou Iwabuchi (S)

Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH